Skip to content
PharmaceuticalsGrenzach-Wyhlen, Baden-WürttembergSIX (Roche Holding AG) No programme known Updated on 18/11/2026

Job cuts at Roche Deutschland: severance pay and your rights

What employees need to know now: status of the cuts, severance practice and your rights.

Updated on 18/11/2026

Employees in GermanyEmployees DE

18,594

As of 2025

RevenueRevenue

€8.9 bn

Group, financial year

HeadquartersHeadquarters

Grenzach-Wyhlen

Baden-Württemberg

Stock exchange listingStock exchange

SIX (Roche Holding AG)

Industry Pharmaceuticals

Severance factorSeverance factor

0.9 to 1.2

Monthly salaries per year

The factor range is our estimate, not a commitment by the company. The actual severance pay depends on the individual case, in particular length of service, age and pay grade.

Severance pay at Roche Deutschland

Severance factor

0.9 to 1.2

Monthly salaries per year of employment

Editorial estimate
  1. 0
  2. 0,5
  3. 1,0
  4. 1,5
  5. 2,0

Vertical line: rule of thumb 0.5, no legal entitlement

Negotiating partner

Works council and IG BCE

Four years of growth, and that is your strongest argument

A redundancy dismissal (betriebsbedingte Kündigung) requires urgent operational grounds, and under Section 1(2) of the Protection Against Dismissal Act (Kündigungsschutzgesetz) the employer bears the burden of proof. For an employer whose workforce in Germany has grown for four years in a row and which invested a record amount in its sites in 2025, that justification is hard to make. This shifts the dispute from whether a dismissal was permitted to what the separation will cost. The fact that investment planning has been under review since October 2026 changes little: there was no mention of job cuts, and the expansion in Penzberg is continuing.

Two collective agreements at one site, and they affect your severance pay

Since 1 January 2019, two chemical industry collective agreements have applied in parallel in Penzberg: the Baden-Württemberg one for everyone who was already there, and the Bavarian one for everyone who joined afterwards. When it was introduced, the pay difference was 10 to 15 per cent.

For severance pay (Abfindung) this is not a minor point. The calculation is factor times monthly salary times years of service, so monthly salary is one of three multipliers. If your pay is 10 to 15 per cent below that of a colleague doing the same job, then with the same factor and the same length of service your severance pay will also be 10 to 15 per cent lower.

Two steps follow from this. First, find out which collective agreement and which pay scale apply to you; this is stated in your employment contract or payslip, and the works council (Betriebsrat) can tell you. Second, if you fall under the grandfathering protection that was publicly promised at the time, check in a social plan (Sozialplan) calculation or a termination agreement (Aufhebungsvertrag) whether the higher calculation basis is really being used. Ask in writing if the figure looks lower than your monthly pay.

The pay difference does not separate you from your colleagues in the social selection

This is often misjudged. Employees are comparable if they are interchangeable in terms of duties and contract, not if they are in the same pay group. Two people doing the same work in a laboratory are comparable, even if different collective agreements apply to them. The selection is then based on the four criteria in Section 1(3) of the Protection Against Dismissal Act: length of service, age, maintenance obligations and severe disability. What an employee costs is not one of them. The employer therefore may not select the more expensive employee for dismissal, nor keep the cheaper one because they are cheaper.

The asymmetry between sites works in your favour

Because the large sites are independent establishments under Section 4(1) of the Works Constitution Act, the social selection (Sozialauswahl) compares you only with the employees at your own site. The duty to look for continued employment, however, expressly extends under Section 1(2) to another establishment of the same company. A vacant position in Mannheim can therefore make your dismissal in Penzberg invalid, without any Mannheim colleague being preferred over you in the selection.

What matters here is which company is named in your employment contract, because in Mannheim alone there are four. The economic situation on which a dismissal must be based is that of your employer, not the total German turnover. Conversely, the duty to offer continued employment extends across the whole company, but in principle not beyond the company boundary into the wider group. The company name on your contract therefore determines where you can demand another position.

How high severance pay at Roche is

We set the severance factor at 1.1 monthly salaries per year of service, with a range of 0.9 to 1.2, which puts it in the upper part of the band for industry, chemicals and pharma. With fifteen years of service and a monthly salary of €5,500, that comes to €90,750, at the lower end €74,250 and at the upper end €99,000.

The figure is supported by four years of workforce growth, record investment, the absence of a job-cut programme, collective bargaining coverage in the chemical sector, works councils at all large sites and an active IG BCE. This makes a redundancy justification difficult, and an employer who wants to push it through anyway will have to pay for it. The figure is held back by the fact that no social plan exists from which a rough scale could be read, so our factor remains a derivation and not an observed practice. Anyone who joined in Penzberg from 2019 onwards also has a lower calculation basis, which does not change the factor but certainly changes the result.

A note for the diabetes division in Mannheim: job cuts there are not documented, but the sales declines are. Anyone working there should be aware of this development, because it determines how credible a redundancy justification would be in an individual case.

The factor is an assessment that we derive from the industry, region, co-determination and economic situation, and is not a commitment by the company. What can ultimately be achieved depends on your specific case, in particular length of service, age and any special protection against dismissal. Further circumstances of the individual case may also apply.

The factor is our estimate, derived from industry, region, co-determination and economic situation, and is not a commitment by the company. Length of service, age and special protection against dismissal can shift the result considerably.

Severance calculator

What you could be entitled to at Roche Deutschland

€
years

Possible severance pay

–

Special protection against dismissal?

€
Have your offer checked for free

Non-binding guidance based on the standard formula, not legal advice. There is only a right to severance pay in exceptional cases; the actual amount depends on the individual case, for example on age, maintenance obligations and whether the dismissal is valid. AbfindungsHero puts you in touch with employment law firms and does not provide legal services itself.

Headcount development

Roche Deutschland, Germany

Source: annual reports

  1. 16,730 19
  2. 18,006 22
  3. 18,242 23
  4. 18,256 24
  5. 18,594 25

Employees of Roche in Germany as at 31 December, taken from the company's own annual announcements of 06.02.2024, 06.03.2025 and 04.03.2026. The figure for 2022 is derived from the announcement for 2023, and the figure for 2019 comes from a press release. No comparable figures are available for 2020 and 2021. Apprentices and dual-study students are included. Scale starts at 13,000, not at zero.

Roche Deutschland: job cuts, severance pay and employees' rights

Roche in Germany: 18,594 employees at four sites

According to the announcement of 4 March 2026, Roche employed 18,594 people in Germany as at 31 December 2025, 338 more than in the previous year, with total turnover of around €8.9 billion, an increase of 4.7 per cent. In 2025, around €719 million was invested in the German sites, which the company describes as a historic high, and almost €3.8 billion since 2020. There were 643 young people in training or dual study programmes. The workforce grew for four years in a row: 18,006 at the end of 2022, 18,242 at the end of 2023, 18,256 at the end of 2024 and 18,594 at the end of 2025. No job-cut programme has been announced.

Sites and companies

The sites are Mannheim, Penzberg, Grenzach-Wyhlen and Ludwigsburg, and the company also names Potsdam and Berlin. Penzberg is the largest site, with about 7,900 employees and 315 apprentices. A diagnostics production centre costing more than €600 million is being built there by 2028, along with an innovation centre opened in February 2026 costing around €300 million and a gene therapy development centre costing around €90 million. In Mannheim the company names Roche Diagnostics GmbH, Roche Diagnostics Deutschland GmbH, Roche Diabetes Care GmbH and Roche Diabetes Care Deutschland GmbH, and in Grenzach-Wyhlen Roche Pharma AG and Roche Deutschland Holding GmbH at the address Emil-Barell-Straße 1. Roche Diagnostics GmbH operates both Mannheim and Penzberg.

Two chemical industry collective agreements at one site

Until the end of 2018, the Baden-Württemberg chemical industry collective agreement was applied at the Penzberg site, even though the site is in Bavaria. The reason lay in the history of the plant: Boehringer Mannheim moved to Penzberg in the 1970s and offered better conditions. Since 1 January 2019, the Bavarian collective agreement has applied to newly hired employees. According to a report of 11 December 2018, pay is 10 to 15 per cent lower as a result. Existing employees received grandfathering protection, expressly including apprentices who started in September 2018 and fixed-term employees who were later taken on permanently. The works council had no co-determination right in this matter, and IG BCE negotiated with the plant management through a collective bargaining committee.

Co-determination and comparison group

Works councils exist at the large sites, and IG BCE is present in Penzberg with a plant group and union representatives. We have no information on the composition of the supervisory board of Roche Pharma AG. Under Section 4(1) of the Works Constitution Act, parts of an establishment count as independent establishments if they are far away from the main establishment or are independent in terms of duties and organisation. For a dismissal, this creates an asymmetry: the social selection under Section 1(3) of the Protection Against Dismissal Act takes place within the establishment, whereas the examination of continued employment under Section 1(2) also extends to another establishment of the same company.

Development of the divisions

For 2025 the company reports pharma at €2.2 billion, up 6.3 per cent, diagnostics at around €909 million, down one per cent, and deliveries to the Roche Group from Germany at €5.8 billion, up five per cent. The Diabetes Care division, which stood at €124 million in 2023 with a decline of 27 per cent and at €105 million in 2024 with a decline of 15.5 per cent, is no longer reported as a separate item for 2025. On 19 October 2026 it was reported that Roche is reviewing its German investment plans because of the federal government's spending restrictions. The approved expansion in Penzberg is said not to be affected, and job cuts were not mentioned.

Have you received a dismissal from a Roche company?

Every case is different, depending on length of service, age, site and any special protection against dismissal. An employment lawyer from our network will assess your situation in a free initial consultation, and the severance pay calculator gives you a ballpark figure in advance.

Affected by job cuts at Roche Deutschland?

Whether an offer is fair can only be judged on the specific case. An employment law firm will assess your situation free of charge.